Clinical trial

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

NCT07428018

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Abemaciclib Normalized identity: abemaciclibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-04-30

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

HER2 + Breast Cancerunresolved

HR Positiveunresolved

Neoadjuvant Therapyunresolved

Interventions

AbemaciclibDRUG · verified · RxNorm: abemaciclib

Sponsors & collaborators

Mario Negri Institute for Pharmacological Researchlead sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanocollaborator

Humanitas Research Hospital IRCCS, Rozzano-Milancollaborator

IRCCS San Raffaelecollaborator

IEO Foundationcollaborator

Papa Giovanni XXIII Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07428018 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.